Clinical Pearls

Guest post by Tom McFarlane

Introduction

Until relatively recently, metastatic castrate resistant prostate cancer (mCRPC) was a disease with very few treatment options available. Patient options were limited to bisphosphonate use for bony metastases and, eventually, chemotherapy of somewhat questionable efficacy with docetaxel and/or mitoxantrone. Since 2010, there have been several promising agents which have emerged in both the pre-chemo and post-chemo settings in mCRPC which have demonstrated progression-free survival (PFS) and overall survival (OS)...Read more

Guest post by Sarah Lutes, Pharmacy Resident, AHS Cancer Control

Currently, the standard practice at Alberta Health Services for newly diagnosed grade 3 and 4 glioma is surgery plus radiation. Patients with 1p/19q-codeleted tumors are also given six cycles of procarbazine, lomustine and vincristine (PCV). There is currently no accepted standard practice for recurrent glioblastoma mulitforme (GBM), however the RESCUE protocol (temazolamide 50mg/m2 given daily) or Avastin® (bevacizumab) are used most often. Other options include...Read more

Guest post by:

Mark Pasetka B.Sc., B.Sc.Pharm., Pharm.D.

Clinical Pharmacy Coordinator

Odette Cancer Centre – Sunnybrook Health Sciences Centre

CAPhO President-Elect

Author's Note: "This was a radiation therapy focused article – i.e., that was limited to 1000 words and therefore, short. I focused on the 5-FU induced cardiotoxicity mostly and provided a very basic overview, not on anthracycline induced cardiotoxicity as is much more commonly reported."

Chemotherapy used for the treatment of cancer carry several significant...Read more

Blog tags: 

Guest post by Melanie Danilak, BSc. Pharm, ACP (Pharmacy Clinical Educator, Cross Cancer Institute, Alberta Health Services)

By now we have all been approached by our patients who are confused about what they have heard on the news or read in the local paper: should I be taking tamoxifen for longer than 5 years? Results of the ATLAS (Adjuvant Tamoxifen: Longer Against Shorter) trial 1 , presented at SABCS 2012 and published in Lancet in March, 2013 had many of us re-thinking our usual "stop after 5 years" advice regarding adjuvant tamoxifen duration. The presentation of...Read more